Related Experiment Video
Updated: Aug 13, 2026
Fluorescent Orthotopic Mouse Model of Pancreatic Cancer
Published on: September 20, 2016
[Establishment of a mouse model for detecting multi-drug resistant minimal residual leukemia cells expressing green
Xiao-Ping Xu1, Xin-Hong Fei, Li Chen
1Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China. xpxu1111@163.com
Abstract:
This study aimed to investigate the pathophysiology and therapy of multi-drug resistant model of minimal residual leukemia in mice. The multi-drug resistant model of minimal residual leukemia was established by using P388/VCR-G cell line expressing enhanced green fluorescent protein (EGFP) and DBA mice. The results showed that P388/VCR-G were inoculated in the abdominal cavities of DBA mice, the incidence of leukemia was 100%. Any of these mice with leukemia could not obtain remission spontaneously. The model of leukemia was sensitive to cyclophosphamide (Cy) and the time of survival was related to the dose of Cy received. The logarithm of cells inoculated in mice correlated regressionally with the dose of Cy. So this model was ideal for research on minimal residual leukemia. The distribution of residual leukemia cells in complete remission was not uniform in different organs including liver, spleen, thymus and bone marrow. Minimal residual leukemia cells could be found by fluorescent microscopy in freezing tissue slice. It is concluded that the multi-drug resistant model of minimal residual leukemia expressing EGFP can be established by using P388/VCR-G cell line and DBA mice. The minimal residual leukemia cells can be observed by fluorescence microscopy in complete remission stage.
Insights
Researchers developed a multi-drug resistant leukemia mouse model using EGFP-expressing cells and DBA mice. This model allows for the observation of minimal residual leukemia cells in complete remission using fluorescence microscopy.
Area of Science:
- * Hematology and Oncology
- * Cancer Biology
- * Mouse Models in Cancer Research
Context:
- * Minimal residual leukemia (MRL) poses a significant challenge in cancer therapy, often leading to relapse.
- * Developing reliable preclinical models is crucial for understanding MRL pathophysiology and evaluating novel therapeutic strategies.
- * Multi-drug resistance (MDR) in leukemia further complicates treatment outcomes and necessitates specialized models for research.
Purpose:
- * To establish and characterize a novel multi-drug resistant model of minimal residual leukemia in mice.
- * To utilize enhanced green fluorescent protein (EGFP) for visualizing residual leukemia cells.
- * To assess the feasibility of using this model for studying leukemia pathophysiology and therapeutic responses.
Summary:
- * A multi-drug resistant leukemia model was successfully established in DBA mice by inoculating P388/VCR-G cells, resulting in a 100% leukemia incidence.
- * The model demonstrated sensitivity to cyclophosphamide (Cy), with survival time dose-dependently correlated with Cy dosage.
- * Minimal residual leukemia cells expressing EGFP were detectable via fluorescence microscopy in various organs (liver, spleen, thymus, bone marrow) during complete remission.
Impact:
- * Provides a robust and reproducible preclinical model for investigating multi-drug resistant minimal residual leukemia.
- * Enables direct visualization and tracking of residual leukemia cells, facilitating deeper understanding of disease persistence.
- * Facilitates the evaluation of therapeutic interventions aimed at eradicating minimal residual disease in resistant leukemia contexts.
